Clinical trials of plasma therapy for Covid-19 patients begins in state
Team Udayavani, Apr 25, 2020, 5:19 PM IST
Bengaluru: The Karnataka government on Saturday commenced convalescent plasma therapy clinical trials for ‘severe’ coronavirus patients in the state.
In a tweet, Medical Education Minister K Sudhakar said, “Happy to announce the commencement of Clinical Trials for Plasma Therapy that holds great promise to treat severely infected #COVID19 patients.
Health Min @sriramulubjp & I initiated this significant step at Victoria Hospital today morning.”
The Minister, who is also leading government efforts against COVID-19 in Bengaluru and is in charge of the state war room had said Convalescent Plasma Therapy was only for patients who are critical, in intensive care units or on ventilator.
Donors have also come forward for this, he had said.
According to officials, patients who have recovered from COVID-19 have been appealed to come forward as donors, as anti-bodies of cured patients will be used to treat critically ill under this therapy.
According to last update, five COVID-19 patients are in ICU in the state.
Health Minister Sriramulu expressed hope that Convalescent Plasma Therapy will be a torchbearer in our fight against the virus.
“Karnataka has taken a lead role as we initiate Phase I clinical trials to use Convalescent Plasma Therapy for severe Covid 19 infected patients.
BMC Victoria hospital took the first step today. We are determined to vanquish this enemy of mankind,” he said in a tweet.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
MUST WATCH
Latest Additions
Kannada Sahitya Sammelana: Food distribution creates stir
Rohit gets hit in nets, practice pitches on slower side
India & Kuwait elevate ties to strategic level; ink defence pact after PM Modi meets top Kuwaiti leaders
In Kuwait, PM Modi meets yoga practitioner, other influencers from Gulf country
Notorious gangster wanted in UAPA case arrested at Nepal border
Thanks for visiting Udayavani
You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.